BioCryst Pharmaceuticals, Inc. (BCRX)
- Previous Close
5.10 - Open
5.14 - Bid 5.31 x 1400
- Ask 5.38 x 1600
- Day's Range
5.07 - 5.35 - 52 Week Range
4.03 - 8.96 - Volume
2,512,524 - Avg. Volume
3,441,214 - Market Cap (intraday)
1.103B - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
-- - EPS (TTM)
-1.07 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
www.biocryst.comRecent News: BCRX
Performance Overview: BCRX
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCRX
Valuation Measures
Market Cap
1.05B
Enterprise Value
1.54B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.82
Price/Book (mrq)
--
Enterprise Value/Revenue
4.34
Enterprise Value/EBITDA
-15.17
Financial Highlights
Profitability and Income Statement
Profit Margin
-58.69%
Return on Assets (ttm)
-10.85%
Return on Equity (ttm)
--
Revenue (ttm)
355.4M
Net Income Avi to Common (ttm)
-208.58M
Diluted EPS (ttm)
-1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
336.55M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-72.42M
Research Analysis: BCRX
Company Insights: BCRX
BCRX does not have Company Insights